TME Pharma N.V. (ALTME.PA)
EUR 0.06
(1.1%)
EUR 0.06
(1.1%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.63 Million | -12.14 Million | -12.38 Million | -5.22 Million | -4.28 Million | -4 Million |
| Net Income | -6.73 Million | -15.12 Million | -14.45 Million | -10.4 Million | -860 Thousand | -10.73 Million |
| Depreciation & Amortization | 144 Thousand | 92 Thousand | 66 Thousand | 63 Thousand | 47 Thousand | 23 Thousand |
| Deferred income taxes | - | - | - | - | - | -76 Thousand |
| Stock-based compensation | 396 Thousand | 589 Thousand | 475 Thousand | 162 Thousand | 107 Thousand | 396 Thousand |
| Change in working capital | -555 Thousand | -720 Thousand | 407 Thousand | 363 Thousand | -371 Thousand | 320 Thousand |
| Other non-cash items | 1.12 Million | 3.02 Million | 1.12 Million | 4.59 Million | -3.2 Million | 6.07 Million |
| Investing Cash Flow | -19 Thousand | -21 Thousand | -14 Thousand | -39 Thousand | -16 Thousand | 66 Thousand |
| Investments in PPE | -19 Thousand | -21 Thousand | -14 Thousand | -39 Thousand | -16 Thousand | -9000.00 |
| Acquisitions | - | - | - | - | - | 75 Thousand |
| Investment purchases | - | - | - | -4.5 Million | - | - |
| Sales/Maturities of investments | - | - | - | 4.5 Million | - | - |
| Other Investing Activities | - | - | - | - | - | 75 Thousand |
| Financing Cash Flow | 3.26 Million | 7.28 Million | 11.49 Million | 14.18 Million | 1.39 Million | 7.6 Million |
| Debt repayment | -61 Thousand | -7374.00 | -4346.00 | -5688.00 | -25.00 | -3.34 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1000.00 | -29 Thousand | -1000.00 | -4000.00 | - | - |
| Common Stock Issuance | 3.38 Million | 85 Thousand | 7.21 Million | 8.79 Million | 1.51 Million | 4.41 Million |
| Other Financing Activities | 3.3 Million | 7.22 Million | 4.28 Million | 5.38 Million | -121 Thousand | 3.18 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -791 Thousand | -580 Thousand | 421 Thousand | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 236 Thousand | -140 Thousand | -14 Thousand | 363 Thousand | -371 Thousand | 320 Thousand |
| Cash at beginning of period | 4.63 Million | 9.45 Million | 10.3 Million | 1.38 Million | 4.29 Million | 622 Thousand |
| Cash at end of period | 2.24 Million | 4.63 Million | 9.45 Million | 10.3 Million | 1.38 Million | 4.29 Million |
| Capital Expenditure | -19 Thousand | -21 Thousand | -14 Thousand | -39 Thousand | -16 Thousand | -9000.00 |
| Effect of forex changes on cash | -1000.00 | 57 Thousand | 49 Thousand | - | - | - |
| Net cash flow / Change in cash | -2.38 Million | -4.82 Million | -848 Thousand | 8.91 Million | -2.9 Million | 3.66 Million |
| Free Cash Flow | -5.65 Million | -12.16 Million | -12.39 Million | -5.26 Million | -4.3 Million | -4 Million |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.24 Million | -1538.50 | -6.73 Million | -1538.50 | -1829.50 | -1829.50 |
| Depreciation & Amortization | 66 Thousand | 33.00 | 144 Thousand | 33.00 | 39.00 | 39.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 97.50 | 396 Thousand | 97.50 | 100.50 | 100.50 |
| Change in working capital | -281 Thousand | 71.00 | -555 Thousand | 71.00 | 47.00 | 47.00 |
| Other non-cash items | 726 Thousand | 216.50 | 1.12 Million | 216.50 | -54.00 | -54.00 |
| Investing Cash Flow | -8000.00 | - | -19 Thousand | - | -9.50 | -9.50 |
| Investments in PPE | -4000.00 | - | -19 Thousand | - | -9.50 | -9.50 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -4000.00 | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 3.2 Million | 738.00 | 3.26 Million | 738.00 | 895.00 | 895.00 |
| Debt repayment | - | - | -61 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -3000.00 | -0.50 | -1000.00 | -0.50 | - | - |
| Common Stock Issuance | 3.26 Million | - | 3.38 Million | - | - | - |
| Other Financing Activities | -61 Thousand | 738.50 | 3.3 Million | 738.50 | 895.00 | 895.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -230 Thousand | - | -791 Thousand | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -51 Thousand | 71.00 | 236 Thousand | 71.00 | 47.00 | 47.00 |
| Cash at beginning of period | 2.2 Million | -381.11 Thousand | 4.63 Million | -381.11 Thousand | 4.63 Million | 812.18 Thousand |
| Cash at end of period | 2.7 Million | -381.5 Thousand | 2.24 Million | -381.5 Thousand | 4.63 Million | -813.00 |
| Capital Expenditure | -4000.00 | - | -19 Thousand | - | -9.50 | -9.50 |
| Effect of forex changes on cash | - | 1.00 | -1000.00 | 1.00 | -1.50 | -1.50 |
| Net cash flow / Change in cash | 503 Thousand | -381.50 | -2.38 Million | -381.50 | - | -813 Thousand |
| Free Cash Flow | -2.74 Million | -1120.50 | -5.65 Million | -1120.50 | -1706.50 | -1706.50 |
BDSX
CNLHP
6066
WGO
NOW
VCSA